MET and cancer: Whereas the therapeutic benefits of MET in many cancer types are known to be mediated by the inhibition of the PI3K/AKT/mTOR-signaling pathways [7, 15], the anti-cancer effects and signaling mechanisms of MET in non-diabetic vs. diabetic women with EC have not been fully characterized.